封面
市场调查报告书
商品编码
1574936

直接作用抗病毒药物市场,按类型、按适应症、按给药途径、按分布、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Direct-acting Antiviral Drug Market, By Type, By Indication, By Route of Administration, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年直接作用抗病毒药物市场规模为2,840,932万美元,2024年至2032年复合年增长率为5.50%。

直接作用抗病毒药物市场-市场动态

提高对肝炎和爱滋病毒的认识和筛检计画。

由于几个关键驱动因素,包括肝炎和爱滋病毒感染率的上升,直接作用抗病毒(DAA)药物的市场正在扩大。随着人们对这些疾病的认识不断增强,越来越多的人接受筛检,从而提高诊断率。改善医疗保健服务和这些疾病的教育也是促成因素。此外,药物开发的最新进展带来了更有效、更快速的治疗方法,使其备受追捧。

美国疾病管制与预防中心 (CDC) 报告称,2021 年,约 25% 的乙型肝炎和丙型肝炎患者被诊断出来,这凸显了对有效治疗的迫切需求。这种意识的提高和筛检计划的改进对于有效管理和治疗病毒感染至关重要。因此,对 DAA 的需求持续成长,塑造了抗病毒治疗的未来。

直接作用抗病毒药物市场-关键见解

根据我们的研究分析师分享的分析,预计全球市场在预测期内(2024-2032 年)每年将以 5.50% 左右的复合年增长率成长

根据类型细分,预计 NS5A 蛋白将在 2023 年显示最大的市场份额

根据适应症细分,2023年C型肝炎病毒为主导类型

根据给药途径细分,2023年口服是领先类型

从分销细分来看,医院药局是2023年的主导类型

按地区划分,北美是 2023 年的主要收入来源

直接作用抗病毒药物市场-細項分析:

全球直接作用抗病毒药物市场根据类型、适应症、给药途径、分布和地区进行细分。

市场依类型分为三类:NS3/4A 蛋白酶、NS5A 蛋白和 NS5B RNA 依赖性 RNA 聚合酶。 NS5A 蛋白质部分是直接作用抗病毒药物市场中最突出的部分。这是因为 NS5A 抑制剂在治疗丙型肝炎方面非常有效,并且被用于许多成功的治疗方案中。它们有助于阻止病毒复製和组装的能力,从而为患者带来更好的结果。对包括 NS5A 抑制剂在内的联合疗法的需求不断增长,使得这一细分市场占据主导地位。因此,NS5A 蛋白药物对于推进丙型肝炎治疗方案和改善患者健康至关重要。

根据适应症,市场分为四类:C型肝炎病毒、爱滋病毒感染/爱滋病、流感和预防。丙型肝炎病毒部分是直接作用抗病毒药物市场中最突出的部分。这是因为C型肝炎影响着全世界数百万人,对有效治疗产生了强烈需求。专为丙型肝炎设计的直接作用抗病毒药物已显示出很高的治癒率并被广泛使用。随着人们对该疾病认识的提高,越来越多的患者寻求这些治疗,从而使这一细分市场占据主导地位。总体而言,丙型肝炎药物在改善健康结果和减少疾病传播方面发挥着至关重要的作用。

直接作用抗病毒药物市场-地理洞察

直接作用抗病毒(DAA)药物市场在北美最大,尤其是美国,对C型肝炎和爱滋病毒的有效治疗有很高的需求。欧洲紧追在后,德国、法国和英国等国家投资抗病毒疗法。亚太地区是一个快速成长的地区,其推动力是医疗保健意识和可近性不断提高,特别是在中国和印度等国家。拉丁美洲也显示出潜力,旨在对抗病毒感染的医疗保健措施不断增加。中东和非洲市场份额较小,但由于医疗基础设施改善,正在逐渐扩大。总体而言,北美地区处于领先地位,但其他地区在 DAA 市场上也取得了重大进展。

直接作用抗病毒药物市场-竞争格局:

直接作用抗病毒 (DAA) 药物市场由吉利德科学 (Gilead Sciences) 和艾伯维 (AbbVie) 等主要参与者引领,这些公司以其对丙型肝炎和爱滋病毒的有效治疗而闻名。其他公司,包括默克和百时美施贵宝,也提供各种抗病毒选择,专注于创新和研究以保持竞争力。许多公司建立合作伙伴关係以增强其产品线并进入更广泛的市场。随着专利到期,Mylan 和 Hetero Labs 等仿製药製造商纷纷介入,提供成本更低的替代品。该市场正在全球范围内扩张,重点是让治疗变得负担得起且易于获得。公司面临监管挑战,需要进行广泛的临床试验才能获得批准。总体而言,市场格局是动态的,其特征是激烈的竞争和对改善病患照护的承诺。

最新进展:

2024年9月,Cocrystal Pharma成功将其口服泛病毒蛋白酶抑制剂CDI-988推进至1期多剂量递增试验,该试验将评估该药物在健康志愿者中的安全性、耐受性和最佳剂量。

目录

第一章:直接作用抗病毒药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章:执行摘要

  • 市场片段
    • 按类型分類的直接作用抗病毒药物市场片段
    • 按适应症分類的直接作用抗病毒药物市场片段
    • 按给药途径分類的直接作用抗病毒药物市场片段
    • 按分布分類的直接作用抗病毒药物市场片段
    • 按国家分類的直接作用抗病毒药物市场片段
    • 按地区分類的直接作用抗病毒药物市场片段
  • 竞争洞察

第 3 章:直接作用抗病毒药物主要市场趋势

  • 直接作用抗病毒药物市场驱动因素
    • 市场驱动因素的影响分析
  • 直接作用抗病毒药物市场限制
    • 市场限制影响分析
  • 直接作用抗病毒药物市场机会
  • 直接作用抗病毒药物市场未来趋势

第 4 章:直接作用抗病毒药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章:直接作用抗病毒药物市场:COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章:直接作用抗病毒药物市场格局

  • 2023年直接作用抗病毒药物市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章:直接作用抗病毒药物市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • NS3/4A蛋白酶
    • NS5A蛋白
    • NS5B RNA依赖性RNA聚合酶

第 8 章:直接作用抗病毒药物市场 - 依适应症分类

  • 概述
    • 按指标分類的细分市场占有率分析
    • 丙型肝炎病毒
    • HIV 感染/爱滋病
    • 流感
    • 预防

第 9 章:直接作用抗病毒药物市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 静脉
    • 口服
    • 皮下
    • 专题

第 10 章:直接作用抗病毒药物市场 - 按分布

  • 概述
    • 按指标分類的细分市场占有率分析
    • 医院药房
    • 网路药局
    • 零售药房

第 11 章:直接作用抗病毒药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美直接作用抗病毒药物主要製造商
    • 北美市场规模和预测(按国家)
    • 北美市场规模和预测(按类型)
    • 北美市场规模和预测(按指标)
    • 北美市场规模与预测(按管理途径)
    • 北美市场规模和预测(按分布)
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲直接作用抗病毒药物主要製造商
    • 欧洲市场规模和预测(按国家)
    • 欧洲市场规模与预测(按类型)
    • 欧洲市场规模与预测(按指标)
    • 欧洲市场规模与预测(按管理途径)
    • 欧洲市场规模与预测(按分布)
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区直接作用抗病毒药物主要製造商
    • 亚太地区市场规模与预测(按国家)
    • 亚太地区市场规模与预测(按类型)
    • 亚太地区市场规模与预测(依指标)
    • 亚太地区市场规模与预测(依管理途径)
    • 亚太地区市场规模与预测(按分布)
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲直接作用抗病毒药物主要製造商
    • 拉丁美洲市场规模与预测(按国家)
    • 拉丁美洲市场规模与预测(按类型)
    • 拉丁美洲市场规模与预测(按指标)
    • 拉丁美洲市场规模与预测(按管理途径)
    • 拉丁美洲市场规模与预测(按分布)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲直接作用抗病毒药物主要製造商
    • 中东和非洲市场规模及预测(按国家)
    • 中东和非洲市场规模及预测(按类型)
    • 中东和非洲市场规模及预测(依指标)
    • 中东和非洲市场规模及预测(按管理途径)
    • 中东和非洲市场规模及预测(按分布)
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第12章:主要供应商分析-直接作用抗病毒药物产业

  • 竞争仪表板
  • 公司简介
    • Gilead Sciences
    • AbbVie
    • Merck & Co.
    • Bristol-Myers Squibb
    • Johnson & Johnson
    • GlaxoSmithKline
    • AstraZeneca
    • Roche
    • Novartis
    • ViiV Healthcare
    • Eisai
    • Hetero Labs
    • Mylan
    • Fujifilm Toyama Chemical
    • Sofinnova Partners

第 13 章:360 度分析师视角

第 14 章:附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3935

REPORT HIGHLIGHT

Direct-acting Antiviral Drug Market size was valued at USD 28,409.32 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

The direct-acting antiviral (DAA) drug market focuses on medications that directly target and block the virus that causes hepatitis and HIV. These drugs work by interfering with the virus's ability to multiply, helping to clear the infection from the body. The drugs are important because they often have fewer side effects and work faster than older treatments. This makes them a preferred option for many patients. As awareness of these diseases grows, more people are seeking DAA drugs, leading to an increase in market demand. Overall, these drugs play a crucial role in improving health outcomes for those affected by viral infections.

Direct-acting Antiviral Drug Market- Market Dynamics

Growing awareness and screening programs for hepatitis and HIV.

The market for direct-acting antiviral (DAA) drugs is expanding due to several key drivers, including the increasing prevalence of hepatitis and HIV infections. As awareness of these diseases grows, more people are getting screened, leading to higher diagnosis rates. Improved healthcare access and education about these conditions are also contributing factors. Moreover, recent advancements in drug development have resulted in more effective treatments that act quickly, making them highly sought after.

The Centers for Disease Control and Prevention (CDC) reported that, in 2021, about 25% of people living with hepatitis B and C were diagnosed, highlighting the urgent need for effective therapies. This rising awareness and improved screening programs are crucial for managing and treating viral infections effectively. As a result, the demand for DAAs continues to grow, shaping the future of antiviral treatments.

Direct-acting Antiviral Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on Type segmentation, The NS5A Protein was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Hepatitis C virus was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution segmentation, Hospital Pharmacy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Direct-acting Antiviral Drug Market- Segmentation Analysis:

The Global Direct-acting Antiviral Drug Market is segmented based on Type, Indication, Route of Administration, Distribution, and Region.

The market is divided into three categories based on Type: NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA Polymerase. The NS5A Protein segment is the most prominent in the direct-acting antiviral drugs market. This is because NS5A inhibitors are highly effective in treating hepatitis C and are used in many successful treatment regimens. They help block the virus's ability to replicate and assemble, leading to better outcomes for patients. The growing demand for combination therapies that include NS5A inhibitors makes this segment dominant. As a result, NS5A Protein drugs are crucial for advancing hepatitis C treatment options and improving patient health.

The market is divided into four categories based on Indications: Hepatitis C Virus, HIV Infection/AIDS, Influenza, and Prophylaxis. The Hepatitis C virus segment is the most prominent in the direct-acting antiviral drug market. This is because hepatitis C affects millions of people worldwide, creating a strong demand for effective treatments. Direct-acting antivirals specifically designed for hepatitis C have shown high cure rates and are widely used. As awareness about the disease increases, more patients are seeking these treatments, making this segment dominant. Overall, hepatitis C drugs play a crucial role in improving health outcomes and reducing the disease's spread.

Direct-acting Antiviral Drug Market- Geographical Insights

The direct-acting antiviral (DAA) drug market is largest in North America, particularly the United States, where there is high demand for effective treatments for hepatitis C and HIV. Europe follows closely, with countries like Germany, France, and the UK investing in antiviral therapies. Asia-Pacific is a rapidly growing region, driven by increasing awareness and access to healthcare, especially in countries like China and India. Latin America also shows potential, with rising healthcare initiatives aimed at combating viral infections. The Middle East and Africa have a smaller market share but are gradually expanding due to improved healthcare infrastructure. Overall, North America leads, but other regions are making significant progress in the DAA market.

Direct-acting Antiviral Drug Market- Competitive Landscape:

The direct-acting antiviral (DAA) drug market is led by major players like Gilead Sciences and AbbVie, known for their effective treatments for hepatitis C and HIV. Other companies, including Merck and Bristol-Myers Squibb, also offer a variety of antiviral options, focusing on innovation and research to stay competitive. Many firms form partnerships to enhance their product lines and reach broader markets. As patents expire, generic manufacturers like Mylan and Hetero Labs enter the scene, providing lower-cost alternatives. The market is expanding globally, with a strong emphasis on making treatments affordable and accessible. Companies face regulatory challenges, needing extensive clinical trials for approval. Overall, the landscape is dynamic, marked by fierce competition and a commitment to improving patient care.

Recent Developments:

In September 2024, Cocrystal Pharma successfully advanced its oral pan-viral protease inhibitor, CDI-988, into Phase 1 multiple-ascending dose trials, which will evaluate the drug's safety, tolerability, and optimal dosing in healthy volunteers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • AbbVie
  • Merck & Co.
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • GlaxoSmithKline
  • AstraZeneca
  • Roche
  • Novartis
  • ViiV Healthcare
  • Eisai
  • Hetero Labs
  • Mylan
  • Fujifilm Toyama Chemical
  • Sofinnova Partners

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • NS3/4A Protease
  • NS5A Protein
  • NS5B RNA-Dependent RNA polymerase

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Hepatitis C Virus
  • HIV Infection/ AIDS
  • Influenza
  • Prophylaxis

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Subcutaneous
  • Topical

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacy
  • Online Drug Store
  • Retail Pharmacy

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Direct-acting Antiviral Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Direct-acting Antiviral Drug Market Snippet by Type
    • 2.1.2. Direct-acting Antiviral Drug Market Snippet by Indication
    • 2.1.3. Direct-acting Antiviral Drug Market Snippet by Route of Administration
    • 2.1.4. Direct-acting Antiviral Drug Market Snippet by Distribution
    • 2.1.5. Direct-acting Antiviral Drug Market Snippet by Country
    • 2.1.6. Direct-acting Antiviral Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Direct-acting Antiviral Drug Key Market Trends

  • 3.1. Direct-acting Antiviral Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Direct-acting Antiviral Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Direct-acting Antiviral Drug Market Opportunities
  • 3.4. Direct-acting Antiviral Drug Market Future Trends

4. Direct-acting Antiviral Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Direct-acting Antiviral Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Direct-acting Antiviral Drug Market Landscape

  • 6.1. Direct-acting Antiviral Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Direct-acting Antiviral Drug Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. NS3/4A Protease
    • 7.1.3. NS5A Protein
    • 7.1.4. NS5B RNA-Dependent RNA polymerase

8. Direct-acting Antiviral Drug Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Hepatitis C Virus
    • 8.1.3. HIV Infection/ AIDS
    • 8.1.4. Influenza
    • 8.1.5. Prophylaxis

9. Direct-acting Antiviral Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intravenous
    • 9.1.3. Oral
    • 9.1.4. Subcutaneous
    • 9.1.5. Topical

10. Direct-acting Antiviral Drug Market - By Distribution

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacy
    • 10.1.3. Online Drug Store
    • 10.1.4. Retail Pharmacy

11. Direct-acting Antiviral Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Direct-acting Antiviral Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Direct-acting Antiviral Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Direct-acting Antiviral Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Direct-acting Antiviral Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Direct-acting Antiviral Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Direct-acting Antiviral Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. AbbVie
    • 12.2.3. Merck & Co.
    • 12.2.4. Bristol-Myers Squibb
    • 12.2.5. Johnson & Johnson
    • 12.2.6. GlaxoSmithKline
    • 12.2.7. AstraZeneca
    • 12.2.8. Roche
    • 12.2.9. Novartis
    • 12.2.10. ViiV Healthcare
    • 12.2.11. Eisai
    • 12.2.12. Hetero Labs
    • 12.2.13. Mylan
    • 12.2.14. Fujifilm Toyama Chemical
    • 12.2.15. Sofinnova Partners

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us